{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.05","upperLimit":"21.82","value":"18.76"},{"groupId":"OG001","lowerLimit":"12.22","upperLimit":"15.87","value":"14.32"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"349"},{"groupId":"OG001","value":"357"}],"units":"Participants"}],"description":"This measure looks at how long all participants live after being placed into a treatment group in the primary study.\n\nOverall Survival (OS) is defined as the time between the date a participant is randomized (assigned to a treatment group) and the date of death from any cause. For participants without documentation of death, OS will be measured up to the last date the participant was known to be alive. If a participant was randomized but had no follow-up information, OS will be counted from the date of randomization.\n\nThis helps to understand whether the treatment can help all participants in the study live longer.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Nivolumab 1 mg/kg plus Ipilimumab 3 mg/kg every three weeks (Q3W) for up to 4 doses followed by Nivolumab monotherapy 480 mg every 4 weeks (Q4W) - Primary Study","id":"OG000","title":"Treatment 1"},{"description":"Participants received Standard of Care treatment every three weeks (Q3W) for up to 6 cycles - Primary Study","id":"OG001","title":"Treatment 2"}],"paramType":"MEDIAN","populationDescription":"All Randomized Participants - Primary Study","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)","title":"Overall Survival (OS) in All Randomized Participants for Primary Study","type":"SECONDARY","unitOfMeasure":"Months"}